NNNN (Anbio Biotechnology) PE Ratio: 84.76 (As of Jul. 04, 2026) — 54% Below Median


NNNN Anbio Biotechnology NNNN
24 GF Score
Price $12.46
! 2 Warning Signs
View Full Analysis

What is Anbio Biotechnology PE Ratio?

Anbio Biotechnology NNNN +2.88% 24 PE Ratio is 84.76 as of Jul. 04, 2026, which is 54% below its 10-year median of 185.37. GuruFocus rates NNNN with a GF Score™ of 24/100. The stock has 2 warning signs investors should review.

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-07-04), Anbio Biotechnology's share price is $12.46. Anbio Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.15. Therefore, Anbio Biotechnology's PE Ratio for today is 84.76.

Good Sign:

Anbio Biotechnology stock PE Ratio (=84.76) is close to 2-year low of 84.76.

During the past 5 years, Anbio Biotechnology's highest PE Ratio was 945.56. The lowest was 84.76. And the median was 185.37.

Anbio Biotechnology's EPS (Diluted) for the six months ended in Dec. 2025 was $0.06. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.15.

As of today (2026-07-04), Anbio Biotechnology's share price is $12.46. Anbio Biotechnology's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was $0.14. Therefore, Anbio Biotechnology's PE Ratio without NRI ratio for today is 92.30.

During the past 5 years, Anbio Biotechnology's highest PE Ratio without NRI was 945.56. The lowest was 92.30. And the median was 200.37.

Anbio Biotechnology's EPS without NRI for the six months ended in Dec. 2025 was $0.06. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was $0.14.

During the past 12 months, Anbio Biotechnology's average EPS without NRI Growth Rate was 151.90% per year. During the past 3 years, the average EPS without NRI Growth Rate was 24.20% per year.

During the past 5 years, Anbio Biotechnology's highest 3-Year average EPS without NRI Growth Rate was 29.30% per year. The lowest was 24.20% per year. And the median was 26.75% per year.

Anbio Biotechnology's EPS (Basic) for the six months ended in Dec. 2025 was $0.06. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.15.

Back to Basics: PE Ratio


Anbio Biotechnology  (NAS:NNNN) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Anbio Biotechnology PE Ratio Related Terms


Anbio Biotechnology PE Ratio Historical Data

* Premium members only.

The historical data trend for Anbio Biotechnology's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anbio Biotechnology PE Ratio Chart

Anbio Biotechnology Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio
N/A N/A N/A N/A 204.56

Anbio Biotechnology Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
PE Ratio Get a 7-Day Free Trial Premium Member Only N/A N/A N/A At Loss 204.56

NNNN vs ANGO, OSUR, UTMD: PE Ratio Comparison

For the Medical Instruments & Supplies subindustry, Anbio Biotechnology's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anbio Biotechnology PE Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Anbio Biotechnology's PE Ratio distribution charts can be found below:

* The bar in red indicates where Anbio Biotechnology's PE Ratio falls into.


NNNN
24GF Score
Anbio Biotechnology NNNN
PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anbio Biotechnology PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Anbio Biotechnology's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=12.46/0.147
=84.76

Anbio Biotechnology's Share Price of today is $12.46.
For company reported semi-annually, Anbio Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.15.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio →
What does a PE Ratio of 84.76 mean?
Anbio Biotechnology (NNNN) has a PE Ratio of 84.76 as of Jul. 04, 2026. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Anbio Biotechnology and its competitors. This is 54% below median its historical median of 185.37. Over the past decade, Anbio Biotechnology's PE Ratio has ranged from 84.76 to 945.56.
Is Anbio Biotechnology's PE Ratio too high?
Anbio Biotechnology's current PE Ratio of 84.76 is 54% below median its 10-year median of 185.37. Over the past 10 years, this metric has ranged from a low of 84.76 to a high of 945.56. Overall, Anbio Biotechnology has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Anbio Biotechnology's PE Ratio compare to ANGO and OSUR?
Anbio Biotechnology's PE Ratio of 84.76 can be compared against companies in the Medical Devices & Instruments industry. Historically, Anbio Biotechnology's own PE Ratio has ranged from 84.76 to 945.56 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio for a Medical Devices & Instruments company?
A good PE Ratio depends on the Medical Devices & Instruments industry context. However, PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio mean?
A high PE Ratio can signal that a stock is expensive relative to its fundamentals. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Anbio Biotechnology and its competitors. Anbio Biotechnology's current PE Ratio is 84.76, which is 54% below median its own 10-year median of 185.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anbio Biotechnology stock overvalued right now?
Anbio Biotechnology (NNNN) has a current PE Ratio of 84.76. The current PE Ratio is 84.76, which is 54% below median its 10-year median of 185.37. Anbio Biotechnology's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio calculated?
PE Ratio is calculated from a company's financial statements. For Anbio Biotechnology (NNNN), the current PE Ratio is 84.76 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anbio Biotechnology Business Description

Address Friedrich-Ebert-Anlage 35-37, Frankfurt am Main, HE, DEU, 60327
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
24GF Score

Get the complete analysis for NNNN

PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.46
Price